Discovery of [1,2,4]triazolo[1,5-a]pyrimidines derivatives as potential anticancer agents

Eur J Med Chem. 2021 Feb 5:211:113108. doi: 10.1016/j.ejmech.2020.113108. Epub 2020 Dec 24.

Abstract

In this work, we reported the discovery of compound 6i with potent antiproliferative activity against MGC-803. Among these compounds, the most potent compound 6i could effectively inhibit MGC-803 (IC50 = 0.96 μM), being around 38-fold selectivity over GES-1. Further underlying mechanism studies indicated that 6i inhibited the colony formation, migration of MGC-803, and exerted anti-proliferative effect by inducing G0/G1 phase arrest in MGC-803 cells. Cell apoptosis was induced by 6i through activating mitochondria-mediated intrinsic pathway and the death receptor-mediated extrinsic pathway. 6i induced cell apoptosis by elevating the level of ROS. Also, 6i up-regulated pro-apoptotic Bax and p53 level, while down-regulating anti-apoptotic Bcl-2 protein expression. Furthermore, acute toxicity experiment indicated 6i exhibited good safety in vivo. Therefore, 6i may be a template for future development of [1,2,4]triazolo [1,5-a]pyrimidine-based anti-cancer agents.

Keywords: Anticancer agents; Antiproliferative activity; [1,2,4]triazolo[1,5-a]pyrimidines.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Cell Proliferation / drug effects*
  • Drug Design
  • Humans
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Pyrimidines